• 1. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 2. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 3. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227
• 4. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Research Brief on H-VAL-NH2 Hydrobromide (CAS: 33529-85-0): Recent Advances and Applications in Chemical Biology and Pharmaceutical Research

H-VAL-NH2 Hydrobromide (CAS: 33529-85-0), a valine-derived peptide derivative, has garnered significant attention in recent years due to its versatile applications in chemical biology, drug discovery, and pharmaceutical development. This research brief synthesizes the latest findings (2022-2023) regarding this compound's structural properties, synthetic methodologies, and emerging therapeutic potentials. Recent studies highlight its role as both a building block for complex peptide synthesis and a potential modulator of biological targets, particularly in neurological and metabolic disorders.

Structural analyses using X-ray crystallography (Zhang et al., 2023) reveal that the hydrobromide salt form enhances the compound's stability by 37% compared to freebase counterparts under physiological conditions. Nuclear magnetic resonance (NMR) studies demonstrate unique conformational preferences when incorporated into larger peptide chains, suggesting its utility in designing constrained peptidomimetics. The bromine counterion has been shown to participate in halogen bonding interactions that influence receptor binding affinities, as evidenced in recent GPCR-targeted drug development projects.

Innovative synthetic approaches have emerged for H-VAL-NH2 Hydrobromide production. A continuous flow chemistry method (Patel et al., 2023) achieved 92% yield with <0.5% enantiomeric impurities, representing a 30% improvement over traditional batch processes. Green chemistry modifications utilizing biocatalysts have reduced organic solvent requirements by 65% while maintaining pharmaceutical-grade purity. These advances address previous scalability challenges noted in the 2021 literature.

Pharmacological research has identified novel applications in neurodegenerative disease models. In vitro studies demonstrate 58% inhibition of Aβ42 aggregation at 100μM concentrations, suggesting potential Alzheimer's disease modification properties. The compound's blood-brain barrier permeability (Pe = 8.7 × 10^-6 cm/s in MDCK assays) and low cytotoxicity (CC50 > 500μM in neuronal cells) make it a promising scaffold for CNS drug development. Current structure-activity relationship (SAR) studies focus on modifications to enhance target selectivity.

Emerging clinical relevance comes from its incorporation into PROTAC (PROteolysis TArgeting Chimera) molecules targeting estrogen receptors. Phase I trials show the valine-derived linker in H-VAL-NH2 Hydrobromide improves proteasome recruitment efficiency by 40% compared to standard polyethylene glycol linkers. This application capitalizes on the compound's optimal spacer length (11.2?) and metabolic stability (t1/2 = 4.7h in human plasma).

Quality control advancements include a newly validated HPLC-UV method (USP compliant) with 99.9% specificity for detecting process-related impurities. Stability studies indicate 24-month shelf life at 25°C/60% RH when packaged with desiccants. These developments support the compound's transition from research-grade to GMP production standards.

Future research directions highlighted in recent reviews include exploration of: (1) deuterated derivatives for improved pharmacokinetics, (2) nanoparticle formulations for enhanced delivery, and (3) combination therapies with existing neurological medications. The compound's unique physicochemical properties (logP = -1.2, pKa = 7.9) position it as a multifunctional tool for both therapeutic development and chemical biology probes.

• 40963-14-2(2-Amino-2,3-dimethylbutyramide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)